All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00125334" target="_blank" >RIV/00216224:14110/21:00125334 - isvavai.cz</a>

  • Result on the web

    <a href="https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical" target="_blank" >https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1182/blood-2021-146221" target="_blank" >10.1182/blood-2021-146221</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

  • Original language description

    Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.

  • Czech name

  • Czech description

Classification

  • Type

    O - Miscellaneous

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    S - Specificky vyzkum na vysokych skolach

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů